Lexington, KY – September 4, 2013.
Omega Ophthalmics LLC (Omega) has announced today that Stephen G. Slade, M.D., FACS has joined their Medical Advisory Board, effective immediately.
Dr. Slade attended Tulane University and the University of Texas in Austin graduating Summa Cum Laude and Phi Beta Kappa with a double major. He attended The University of Texas Medical School with a final, elective year spent at Guy’s Hospital, London. He completed a residency at the LSU Eye Center in New Orleans and fellowships in corneal surgery at Baylor College of Medicine in Houston and in New York, New York on Project ORBIS. Dr. Slade is a Fellow of the American Academy of Ophthalmology and the American College of Surgeons.
“Steve Slade is a true pioneer in ophthalmology,” states Rick Ifland, CEO of Omega. “It is an honor to have him as part of our team.”
In 1991, Dr. Slade, along with Stephen Brint, MD, performed the first LASIK surgery in the United States. Later he performed the first Custom LASIK ablation based on topography in the United States. Dr. Slade has remained on the cutting edge, having the nation’s first and longest experience with Laser Cataract Surgery, LASIK, Femtosecond Laser LASIK and accommodating intraocular lenses for cataract surgery (Crystalens). Dr. Slade was the lead investigator and presented the data to the FDA for panel approval for both the Crystalens and the implantable contact lens, ICL. As part of the Crystalens trial, Dr. Slade implanted the first intraocular lens for presbyopia in North America.
ABOUT OMEGA OPHTHALMICS
Omega Ophthalmics is a medical device company making significant advancements in the global ophthalmology industry through its patent-pending, proprietary technologies for intraocular lenses, capsular bags, and high technology applications within the eye. Founded by Gary Wörtz, MD and Rick Ifland, Omega is headquartered in Lexington, KY.
For more information about Omega Ophthalmics, contact Rick Ifland, CEO.
For more information about Omega’s technology, contact Gary Wörtz, MD, CMO.